My Account Log in

2 options

Military use of drugs not yet approved by the FDA for CW/BW defense : lessons from the Gulf War / Richard A. Rettig [et al.]

EBSCOhost Academic eBook Collection (North America) Available online

View online

RAND Reports Available online

View online
Format:
Book
Government document
Author/Creator:
Rettig, Richard A., Author.
Contributor:
United States. Department of Defense, Content Provider.
National Defense Research Institute (U.S.), Content Provider.
United States. Department of Defense. Office of the Secretary of Defense, Content Provider.
Series:
Gulf War illnesses series
Language:
English
Subjects (All):
Chemical warfare--Security measures--United States.
Chemical warfare.
Biological warfare--Security measures--United States.
Biological warfare.
Gases, Asphyxiating and poisonous--Antagonists.
Gases, Asphyxiating and poisonous.
Vaccines--Chemical warfare.
Vaccines.
Informed consent (Medical law)--United States.
Informed consent (Medical law).
Involuntary treatment--United States.
Involuntary treatment.
Persian Gulf War, 1991--Chemical warfare.
Persian Gulf War, 1991.
United States--Armed Forces--Medical care.
United States.
Physical Description:
1 online resource (xx, 102 pages).
Place of Publication:
Santa Monica, Ca : Rand ; 1999
Language Note:
English
Summary:
The confrontation that began when Iraq invaded Kuwait in August 1990 brought with it the threat that chemical and biological weapons might be used against the more than half a million military personnel the United States deployed to the region. To protect these troops from such threats, the Department of Defense wished to use drugs and vaccines that, not having been tested for use in these specific situations, were considered "investigational" by the federal Food and Drug Administration. This report examines the history of the Interim Rule, adopted in December 21, 1990, that authorized the Commissioner of Food and Drugs to waive informed consent for the use of investigational drugs and vaccines for certain military uses; how this authority was used for pyridostigmine bromide and botulinum toxoid during the Gulf War; and the subsequent controversy surrounding the rule, its application, and its implications. The report then analyzes the issues the Interim Rule raised when investigational drugs are used for such purposes and makes recommendations for dealing with similar situations in the future.
Notes:
Bibliographic Level Mode of Issuance: Monograph
ISBN:
0-585-24547-9

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account